Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too

Executive Summary

US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.


Related Content

Novo's Semaglutide: Retinopathy Events Will Draw US FDA Panel's Focus
Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
Can A Safety Study Support A Superiority Claim? Barely, FDA Advisors Say
Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee
Jardiance's CV Benefit: Can A Single Study Carry The Day At FDA?
Novo Will Go After MACE Indication For Victoza Based On LEADER
Empagliflozin CV Outcomes Data: Is Sum Of The Parts Greater Than Whole?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts